Chemotherapy Decision-Making in Early Breast Cancer

Video

This video discusses chemotherapy decision-making in early-stage breast cancer, and reviews tools such as PREDICT 2.0 and the MammaPrint 70-gene assay that can help guide treatment.

In this video, N. Lynn Henry, MD, PhD, of the University of Utah Huntsman Cancer Institute, discusses chemotherapy decision-making in early-stage breast cancer, and reviews tools such as PREDICT 2.0 and the MammaPrint 70-gene assay that can help guide treatment.

Henry spoke on this topic at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held last month in Chicago.

Recent Videos
4 experts in this video
2 experts in this video
2 experts in this video
4 experts in this video
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
A paucity of prospective, well-vetted data to guide therapy in patients with rare lymphomas may result in a reliance on expert consensus guidelines.
Related Content